OPKO Health Q1 net loss $55.4M; completes ModeX acquisition for $300M and GeneDx sale

OPKO HEALTH, INC.

2022-Q1 EPS reported -$0.08 revenue$329,219,000

Q1 consolidated revenue $329.2M (down from $545.2M); net loss $55.4M ($0.08) vs net income $31.1M ($0.05) prior year.
Diagnostics revenue $286.6M (down from $507.0M) due to lower COVID-19 testing: 2.0M tests vs 4.1M YoY.
Acquired ModeX Therapeutics for $300M in OPKO common stock; Dr. Elias Zerhouni named President and Vice Chairman.
Closed sale of GeneDx to Sema4 for ~$322M upfront (cash + stock) plus up to $150M in milestones.
Pfizer launched NGENLA in Germany/Japan; OPKO earned $85M milestones. RAYALDEE launched in Germany by Vifor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.